News and Announcements
Hot Calibration Run of the OncoSil Device
- Published August 18, 2016 4:24PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
18th August 2016, ASX Announcement
OncoSil Medical Limited (ASX: OSL) (OncoSil Medical or the Company), a late stage medical device company focused on localised treatments for patients with pancreatic and liver cancer, is pleased to announce that it has successfully completed a supply chain validation process including the first hot (radioactive) calibration delivery of OncoSil™.
In preparation for the commencement of the Company’s planned global clinical study of OncoSil™ for the treatment of pancreatic cancer (Oncopac-1) and the commercialisation of OncoSil™ subject to attainment of CE Mark, the Company restarted de-novo manufacturing of OncoSil™ microparticles in January 2016. The manufacturing, supply chain validation and delivery to clinical and commercial centres of OncoSil™ product is a key step to commercial sales and the treatment of patients in the OncoPac-1 Study.
To view the full announcement, please click on the button below.
Company Updates
BlackRock has named the next Economy. What this latest paper means for Private Market Investors.
BlackRock has put a name on something the smart money has been circling for two years. Its digital assets research team calls it the machine-native economy. The thesis fits in one line. AI is machine-native intelligence. Digital assets are machine-native money. Both are built on the same architecture, and they are converging into a single […]
Where’s the beef? Blackstone just answered the AI question.
In 1984, a fast food ad asked a question that became a catchphrase. Where’s the beef? Jon Gray, President of Blackstone, used that line this month in front of global LPs. It is the question every capital allocator is asking about AI. Trillions of dollars are going into chips, data centres and power. That is […]
The Best of Both Worlds: How Omnique Fund is Rewiring Real World Assets via Tokenisation
For decades, the playbook for Australia’s wholesale investors has remained relatively unchanged: pick between the slow-moving, illiquid reliability of tangible assets like property and gold, or chase the frictionless, high-velocity liquidity of public equity and digital markets. But as macroeconomic volatility spikes and a structural housing deficit reshapes private debt demand, sophisticated investors are demanding […]
Backed By Leading Investment Groups and Family Offices
